Results 51 to 60 of about 26,835 (181)

A computationally engineered RAS rheostat reveals RAS-ERK signaling dynamics. [PDF]

open access: yes, 2016
Synthetic protein switches controlled with user-defined inputs are powerful tools for studying and controlling dynamic cellular processes. To date, these approaches have relied primarily on intermolecular regulation.
Baker, David   +12 more
core   +2 more sources

Molecular Diagnostics in Thyroid Nodules: Current Applications, Clinical Value, and Future Perspective

open access: yesMed Research, EarlyView.
ABSTRACT Molecular diagnostics have become an important adjunct to ultrasonography and fine‐needle aspiration (FNA) for thyroid nodules, especially in Bethesda III/IV cytology where malignancy risk is uncertain. This narrative review summarizes the diagnostic and prognostic value of key genomic drivers (BRAF V600E, RAS, RET, TERT, and selected fusions)
Guohui Xiao   +14 more
wiley   +1 more source

SREBP1-dependent de novo fatty acid synthesis gene expression is elevated in malignant melanoma and represents a cellular survival trait. [PDF]

open access: yes, 2019
de novo fatty acid biosynthesis (DNFA) is a hallmark adaptation of many cancers that supports survival, proliferation, and metastasis. Here we elucidate previously unexplored aspects of transcription regulation and clinical relevance of DNFA in cancers ...
Näär, Anders M, Wu, Su
core  

Benign Keratoses With Inverted Follicular Keratosis‐Like Features in a Patient Receiving Ripretinib: A Case Report

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Inverted follicular keratosis (IFK) is a rare benign neoplasm of the follicular infundibulum and typically presents as a solitary, nonpigmented verrucous papule on the head and neck of older males and can mimic viral warts, basal cell carcinoma (BCC), or squamous cell carcinoma (SCC). We report a case of multiple benign keratoses with IFK‐like
Elsayed Ibrahim   +5 more
wiley   +1 more source

Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas [PDF]

open access: yes, 2018
FDA-approved BRAF inhibitors produce high response rates and improve overall survival in patients with BRAF V600E/K-mutant melanoma, but are linked to pathologies associated with paradoxical ERK1/2 activation in wild-type BRAF cells.
Aplin, Andrew E.   +10 more
core   +1 more source

Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model. [PDF]

open access: yes, 2017
An excessive requirement for methionine termed methionine dependence, appears to be a general metabolic defect in cancer. We have previously shown that cancer-cell growth can be selectively arrested by methionine deprivation such as with recombinant ...
Chmielowski, Bartosz   +15 more
core   +2 more sources

Advances and Challenges in the Multidisciplinary Treatment of Retroperitoneal Infantile Fibrosarcoma in Early Life

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Background and Aims Retroperitoneal Infantile Fibrosarcoma (RIFS) is a rare, locally aggressive pediatric soft tissue tumor. Its retroperitoneal location poses challenges due to proximity and potential invasion of critical structures such as the inferior vena cava (IVC).
Gaia Brunetti   +8 more
wiley   +1 more source

RSK2 promotes melanoma cell proliferation and vemurafenib resistance via upregulating cyclin D1

open access: yesFrontiers in Pharmacology, 2022
BRAF inhibitors are commonly used in targeted therapies for melanoma patients harboring BRAFV600E mutant. Despite the benefit of vemurafenib therapy, acquired resistance during or after treatment remains a major obstacle in BRAFV600E mutant melanoma ...
Hai-Zhou Wu   +13 more
doaj   +1 more source

KMT2A promotes melanoma cell growth by targeting hTERT signaling pathway. [PDF]

open access: yes, 2017
Melanoma is an aggressive cutaneous malignancy, illuminating the exact mechanisms and finding novel therapeutic targets are urgently needed. In this study, we identified KMT2A as a potential target, which promoted the growth of human melanoma cells ...
Chen, Miao   +18 more
core   +1 more source

Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series

open access: yesTherapeutic Advances in Medical Oncology, 2014
The selective BRAF inhibitors, vemurafenib and dabrafenib, yield high response rates and improved overall survival in patients with BRAF V600E-mutant metastatic melanoma.
Andrew J. Dooley   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy